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NRAS mutation in melanoma has been associated with aggressive tumor biology and poor prognosis. 
Although targeted therapy has been tested for NRAS mutated melanoma, response rates still appear 
much weaker, than in BRAF mutated melanoma. While plenty of cell lines exist, however, only few 
melanogenic cell lines retain their in vivo characteristics. In this work we present an intensively 
pigmented and well-characterized cell line derived from a highly aggressive NRAS mutated cutaneous 
melanoma, named MUG-Mel2. We present the clinical course, unique morphology, angiogenic 
properties, growth characteristics using in vivo experiments and 3D cell culture, and results of the 
exome gene sequencing of an intensively pigmented melanogenic cell line MUG-Mel2, derived from a 
cutaneous metastasis of an aggressive NRAS p. Q61R mutated melanoma. Amongst several genetic 
alterations, mutations in GRIN2A, CREBP, PIK3C2G, ATM, and ATR were present. These mutations, 
known to reinforce DNA repair problems in melanoma, might serve as potential treatment targets. The 
aggressive and fast growing behavior in animal models and the obtained phenotype in 3D culture reveal 
a perfect model for research in the field of NRAS mutated melanoma.
The term melanoma embraces a large spectrum of malignant melanocytic proliferations that differ with respect to 
their clinical morphology, epidemiology, growth pattern and, genetic alterations. Mutations in the BRAF (B-Raf 
proto-oncogene, serine/threonine kinase) and NRAS (neuroblastoma rat sarcoma viral oncogene) have been 
identified as key drivers in melanoma progression. In approximately 50% of cutaneous melanomas BRAF muta-
tions are found, while about 25% of melanomas harbor mutations in NRAS1. The two alterations appear to be 
mutually exclusive.
NRAS mutations lead to activation of the MAPK and PI3K/Akt/mTOR pathway2 and are present among 
melanoma in various other cancers such as leukemia, lung and colorectal cancer3. In melanoma, the vast majority 
(90%) of mutations are located in codon 61, represented mostly by p. Q61K and p.Q61R mutations4, 5. In contrast 
to BRAF mutated melanoma, the clinical and molecular characteristics of NRAS mutated melanoma subtypes 
are less well documented. Current literature however, suggests a more aggressive nature of NRAS mutated mel-
anomas compared to BRAF mutated or wildtype melanomas. In particular the NRAS Q61 mutation has been 
shown to be associated with poor outcome6. Besides the biological differences between NRAS and BRAF mutated 
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melanoma, the poor outcome might also be related to a weaker response of NRAS mutated melanoma compared 
to BRAF mutated melanomas to current targeted therapy (i.e. vemurafenib, dabrafenib with or without MAPK 
inhibitors)7. For these reasons, the development of melanoma cell lines that retain comparable characteristics as 
in the in vivo state are crucial to search for novel treatment options in this particular subset of NRAS mutated 
melanomas.
To obtain the morphology in vitro as close as possible to the in vivo state we cultured the cell line in a nano-
fibrillar cellulose (NFC) hydrogel. When considering suitable scaffold for the 3D-culture of MUG-Mel2, some 
important attributes were taken into account. The material should be possible to be optimized for MUG-Mel2 due 
its novel status, and the scaffold should also be removable for further analysis, such as immunohistochemistry. As 
one of the few completely removable 3D-scaffolds available8, NFC was considered a good option for the study. In 
addition that the NFC hydrogel’s concentration can be tailored for every cell line8, resulting into suitable scaffold 
stiffness for the cell line in question, the material has also been found to be able to support organotypic growth of 
the cell line HepG2, indicating a promising 3D environment modelling for a neoplastic cell line9.
Herein, we present the clinical, biological and genetic characteristics of a peculiar melanogenic cell line - 
named MUG-Mel2, derived from a fresh biopsy tissue of a cutaneous metastasis of a highly aggressive NRAS 
p.Q61R mutated melanoma. For the genetic analysis we performed copy number variations, targeted exome 
sequencing and determined pathway analyzes. The unique phenotype of the melanoma - the stable brown color-
ing, could be preserved over all passages in cell culture, which in turn is beneficially convenient and, useful for 
easy detection in vivo experiments. Cell culture models that maintain characteristics of the in vivo state are crucial 
research models to explore novel and relevant targets for treatment.
Results
Cell Line Establishment. The MUG-Mel2 cell line was obtained from a cutaneous primary, ulcerated mel-
anoma on the left shoulder. Clinical course time line is described in Fig. 1. Four months after wide surgical 
excision of the primary melanoma, the patient developed multiple cutaneous satellite metastases around the 
scar with progressive spread all over the body (Fig. 2A). Tumor pieces were cultured in vitro, no melanoma cell 
growth can be obtained. After three months of the treatment with MEK inhibitor (binetimib in a trial), there was 
no objective evidence of response as the patient continued to develop multiple cutaneous metastases (Fig. 2B). 
After tumor therapy, tumor pieces were given in culture, a massive growth of the cells occurred and the cell line 
MUG-Mel2 was established. Right from the beginning, culture revealed prominent cells with triangular den-
dritic morphology as typically seen in melanoma and surrounding fibroblast-like cells (Fig. 2C). After ten days, 
exclusively melanoma cells were further cultured (Fig. 2D). During cell line cultivation, cells were regularly cry-
opreserved. Although cells were passaged more than 100 times and retained in culture for more than 12 months, 
no significant changes in their morphology were observed. For cell line identification we used Power Plex® 16, 
frozen primary tumor and MUG-Mel 2 passage nine and passage 60, all showed the same STR profile in all mark-
ers (Suppl Table 1). Immunostaining of MUG-Mel2 revealed high expression of HMB-45 (Fig. 2E), Melan-A 
(Fig. 2F), Tyrosinase (Fig. 2G), and a weak expression of S100 (Fig. 2H). Cell growth rate was determined by real-
time monitoring xCELLigence and doubling time of 38.19 ± 4.09 hours was calculated. Cell size of 20.59 µm was 
measured by Casy cell counting.
Genetic Characterization. In order to characterize the cell line at the genetic level, we analyzed copy 
numbers using low-coverage whole genome sequencing. Genome wide copy numbers inferred from the counts 
were observed across the genome. MUG-Mel2 showed a variety of copy number aberrations, including gains 
of chromosome 1p, 3, 7, 8, 9q, 12, 14, 15, 16, 17q, 20 as well as losses of chromosomes 1q, 4, 5, 9p, 10, 13, 17p 
and 18 (Fig. 2I), These genetic alterations are highly concordant with available copy number data for melanoma 
from the public Progenetix database (Suppl Figure 1). CFU assays to confirm the tumorigenicity revealed a total 
of 26.83 ± 4.79 clones after a period of 30 days, a representative example is presented in Fig. 2J. DNA index 
was calculated by analyzing the geometric mean of MUG-Mel2 78.00/ geometric mean of MNC 48.68. A DNA 
index of 1.6 was calculated, which means that the tumor cells were hyperdiploid. Cell cycle of spiked MNC and 
MUG-Mel2 analysed with two cell cycles are presented in Fig. 2K. Phosphorylation of ERK, a key player of RAS 
oncogenic pathway was determined by Western blot. Compared with WM 164 (BRAF mutated) cell line a signifi-
cant increase of ERK phosphorylation was detected (Fig. 2L). Due to this putative activation, we checked available 
low-coverage whole genome sequencing data for focal amplifications of genes involved in the respective pathway. 
Figure 1. Clinical course and date of MUG-Mel2 cell line establishment.
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However, no focal amplifications were observed for AKT, BRAF, EGFR, KRAS, MAPK1-15, MEK, NRAS or 
PIK3CA (Suppl Table 2).
Ex ovo CAM Assay. In the ex ovo CAM assay MUG-Mel2 formed intensively pigmented tumor masses within 
three days. Macroscopic observation revealed attraction of numerous vessels that developed radially towards the 
onplants and the presence of loco-regional metastases with solitary evading tumor cells surrounded by newly 
formed blood vessels (Fig. 3A–C). HE staining revealed that solid tumor samples were strongly connate to the 
CAM with outgrowth of the tumor invading avian vasculature (Fig. 3D), which can also be detected by desmin 
staining (Fig. 3F). Proliferating cells were detected by Ki-67 staining and were shown to be uniformely distributed 
throughout the xenograft (Fig. 3E). MUG-Mel2 cells also highly express vimentin, a cytoskeletal protein, which 
is present in several melanoma cells (Fig. 3G).
Xenotransplants confirmed tumorigenicity of MUG-Mel2. The melanoma cells were easily detectable 
because of the intense pigmentations. To determine tumorigenicity of MUG-Mel2, cells were injected first into 
NOD/SCID/Il −2rznull (NSG) mice. All three (3/3) xenotransplants developed black nodules after 10 days. The 
same evolution and growth was also detectable in all xenotransplants (5/5) in nude mice at 100% (Fig. 4A–C). To 
verify the melanoma growing in mice, IHC were performed, showing a strong expression of HMB-45 (Fig. 4D), 
strong expression of Melan-A (Fig. 4E), and a strong expression of S100 (Fig. 4F). From each mouse liver, spleen, 
heart, kidney and lung was examined, no metastases were found within one month. Tumor material from NSG 
Figure 2. Male patient with cutaneous metastases appearing shortly after wide surgical excision of a primary 
melanoma on his left shoulder (A). Rapid progression of cutaneous metastases three months after the excision 
of the primary melanoma irrespective of targeted therapy (B), outgrowth of melanoma tumor cells surrounded 
by stroma cells (C), MUG-Mel2 cell line after ten days (D). Immunohistochemistry revealed in a strong HMB-
45 expression (E), strong Melan-A expression (F) strong Tyrosinase expression (G) and a weak S-100 expression 
(H). Copy number variation profile of MUG-Mel2 passage 89. Regions with log2 ratios > 0.2 that indicate gains 
of chromosomal material are shown in red and those with log2 ratios < −0.2 that indicate loss of chromosomal 
material are shown in blue. Balanced genomic regions are depicted in green (I). Tumorigenicity was performed 
by CFU assay (J). DNA index was calculated by analyzing the geometric mean of MUG-Mel2 and MNC. 
DNA index of 1.6 was calculated, which means that the tumor cells were hyperdiploid, cell cycle was analysed 
by ModFit software 4.1, red peak indicats G1 peak of MNC, yellow peak G1 peak of MUG-Mel2 cells (K). 
Phosphorylation of ERK was determined by Western blot, WM164 was used as control cell line (L).
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mice was mechanically dissociated and again established in cell culture (xMUG-Mel2). Both, MUG-Mel2 and 
xMUG-Mel2 were seeded into 96 wells, MTS assays were performed in order to test whether the proliferation rate 
can be increased after in vivo stimulation. There were no significant differences regarding the growth behavior of 
MUG-Mel2 and xMUG-Mel2 (data not shown).
MUG-Mel2 cells were able to form spheroids. The ability of MUG-Mel2 to form spheroids could be 
achieved by cultivation in NFC scaffolds, which was tested by using three different concentrations of NFC and 
two cell concentrations. The morphology of the spheroids after two days and after five days is shown in Fig. 5A,B. 
To indicate the viability of 3D cultures, Calcein was used, while only live cells can hydrolyze the cell-permable 
dye; cell nuclei were counterstained with DAPI (Fig. 5C). The typical morphology of the melanoma cells has been 
Figure 3. Ex ovo CAM assay: MUG-Mel2 onplants formed highly pigmented tumors within the silicone ring on 
the CAM surface after three days of incubation. Avian vessels developed radially towards the onplants (A: 10x 
magnification, B: 25x magnification), loco-regional metastases with solitary evading tumor cells surrounded 
by newly formed blood vessels were present (C: 63x magnification). Morphological analysis of hematoxylin/
eosin stained sections revealed strong interaction of MUG-Mel2 cells with the CAM mesenchyme and invasion 
of tumor cells from the primary onplant site into the surrounding CAM tissue (D). MUG-Mel2 cells are mitotic 
active (Ki-67 staining) (E), tumor-driven neoangiogenesis was detected with anti-desmin (F). MUG-Mel2 cells 
express the tumor biomarker vimentin (G) (400x magnification, scale bar = 20 µm).
Figure 4. Tumorigenicity: MUG-Mel2 growing in NSG mice (A), black tumor was visible within 10 days (B). 
Separated tumor from nude mouse (C). IHC from xenotransplantations with strong HMB-45 expression (D), 
strong Melanin-A expression (E), and strong S-100 expression (F).
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preserved from the human tumor tissue, via the xenograft, to the 3D culture (Fig. 5A–F). Cells cultured in NFC 
showed a strong pigementation in the cytoplasm of melanoma cells (Fig. 5F).
Somatic variants of the MUG-Mel2 cell line. Targeted exome sequencing was used to detect somatic 
variants in the tumor cell line. We identified a total of 647 somatic mutations, affecting a total of 451 genes, and 
a mutational rate of 54.5 mutation/Mb (Suppl Tables S3 and S4). Of the overall mutations, 293 were missense, 6 
nonsense (stop-gain), and 10 frameshift, while 186 were synonymous and 152 were located in UTR, introns or 
intergenic regions. The 309 possibly damaging mutations (including missense, nonsense and frameshift) affected 
a total of 229 genes (Table S3). To confirm this analysis, we also sequenced with the same approach MUG-Mel2 
P9 and P60. The overall number of mutations was quite stable across the passages (309 in primary tumor, 305 in 
P9 and 272 in P60). As well, over 60% of mutations detected in the primary tumor were confirmed at the later 
passages suggesting an overall stability of the genome of these cells (Table S5). The majority of mutations were 
transitions (66% of overall somatic mutations and 66% of the damaging somatic mutations), with a striking 
prevalence of C > T transitions (50% of overall somatic mutations and 53% of the damaging somatic mutations) 
(Fig. 6A,B). Ingenuity Pathway Analysis of the 229 genes with at least one damaging mutation gave an insight 
of which pathways or biological functions are related to these genes. For better understanding, Table 1 presents 
a summary of the top 16 pathways resulting from the p-values, indicates the amount of mutation in genes. The 
Figure 5. Morphology of MUG-Mel2 in 3D cultures. Cells formed spheroids in nanofibrillar cellulose (NFC) 
after two days in a concentration of 0.4% (A: 50x magnification), after five days in a concentration of 0.4% (B: 
50x magnification); intensive brown staining was observed. Calcein staining (green) revealed the viability of 
the spheroids, nuclei were counterstained with DAPI (blue) (C). HE staining of human tumor tissue (D), tumor 
xenotransplantat (E), and 3D culture of MUG-Mel2 cells showed typical melanoma morphology and pigmented 
cytoplasm (F).
Figure 6. Relative frequencies of each type of nucleotide substitution (A) and of indels, transitions and 
transversions (B) among the overall somatic mutations and among the damaging somatic mutations detected in 
MUG-Mel 2 cell line.
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most common genes in that pathway are ATM (14 times), PIK3C2G (14 times), NRAS (11 times), HLA-DRB1 
(11 times), and HLA-DRB5 (11 times) which clearly indicates the importance of those mutations. These genes are 
among other represented in ‘CREB Signaling in Neurons’ (p-value 3.02E-05), mutated genes: GRIN2A, PLCE1, 
NRAS, CREBBP, PIK3C2G, GRM6, PRKD3, GRIA3, ATM, GRIK1 (Fig. 7). Looking deeper at the ATM mutation, 
it might be visible in the ‘Molecular Mechanisms of Cancer’ (p-value 0.0199) pathway (Fig. 8). We found a high 
mutational burden in the overall target (386 mutation/Mb), the genes which are listed in Table S2 with decreasing 
damaging mutation burden, the most highly mutated genes are KIR2DL1, KIR2DL3, AQP7, HLA-DRB5, SAA2, 
HLA-A, KIR3DL1, HLA-DPB1, HLA-C, CCL22 are involved in immune response, whereas mutated genes are 
enriched for metabolic, immunorelated and cancer-related pathways.
Discussion
MUG-Mel2 is a new established cell line, characterized by mutations among others in NRAS p.Q61R, GRIN2A 
and DNA damaged genes. The peculiarity of the cell line is that it was cultured from a highly aggressive cutaneous 
metastasis, which did not respond either to targeted, immuno- or cytotoxic therapy despite revealing a mutation 
in NRAS p.Q61R.
The cell line exhibits well known melanoma markers such as Melan-A, S-100, Tyrosinase, and HMB-45. 
Remarkably, the markers and the peculiar cell morphology of heavily pigmented dendritic cells were preserved 
even after long-term culture conditions in 2D as well as in 3D culture. 3D and co-culture systems mimic the in 
Ingenuity 
Canonical 
Pathways (p-value) Ratio
No overlap 
with dataset Molecules
Crosstalk between 
Dendritic Cells 
and Natural Killer 
Cells
4,7863E-07 1,01E-01 80/89 (90%) KIR2DL1/KIR2DL3,KIR3DL1,HLA-DRB1,HLA-A,HLA-C,KIR3DL2,KIR2DL4,MICA,HLA-DRB5
IL-4 Signaling 4,2658E-06 9,20E-02 79/87 (91%) NRAS,HLA-DRB1,TYK2,PIK3C2G,HLA-DQB1,JAK2,HLA-DRB5,ATM
Synaptic Long 
Term Potentiation 5,88844E-06 7,50E-02 111/120 (93%) GRIN2A,PLCE1,NRAS,CREBBP,GRM6,CACNA1C,PRKD3,GRIA3,GRIN3A
Dendritic Cell 
Maturation 6,76083E-06 5,79E-02 179/190 (94%) PLCE1,HLA-DRB1,HLA-A,HLA-C,CREBBP,PIK3C2G,HLA-DQB1,JAK2,FCGR3A/FCGR3B,HLA-DRB5,ATM
Natural Killer Cell 
Signaling 6,76083E-06 7,38E-02 113/122 (93%) KIR2DL1/KIR2DL3,KIR3DL1,NRAS,PIK3C2G,KIR3DL2,KIR2DL4,PRKD3,FCGR3A/FCGR3B,ATM
Autoimmune 
Thyroid Disease 
Signaling
1,04713E-05 1,28E-01 41/47 (87%) HLA-DRB1,HLA-A,HLA-C,HLA-DQB1,HLA-DRB5,TG
Graft-versus-Host 
Disease Signaling 1,1749E-05 1,25E-01 42/48 (88%) KIR2DL1/KIR2DL3,HLA-DRB1,HLA-A,HLA-C,HLA-DQB1,HLA-DRB5
Amyotrophic 
Lateral Sclerosis 
Signaling
2,63027E-05 7,21E-02 103/111 (93%) GRIN2A,PIK3C2G,CACNA1C,NEFH,GRIA3,ATM,GRIK1,GRIN3A
CREB Signaling 
in Neurons 3,01995E-05 5,43E-02 174/184 (95%) GRIN2A,PLCE1,NRAS,CREBBP,PIK3C2G,GRM6,PRKD3,GRIA3,ATM,GRIK1
Neuropathic 
Pain Signaling 
In Dorsal Horn 
Neurons
3,16228E-05 7,02E-02 106/114 (93%) GRIN2A,PLCE1,PIK3C2G,GRM6,PRKD3,GRIA3,ATM,GRIN3A
Glutamate 
Receptor 
Signaling
3,23594E-05 1,05E-01 51/57 (89%) GRIN2A,GRM6,SLC1A1,GRIA3,GRIK1,GRIN3A
Antigen 
Presentation 
Pathway
4,46684E-05 1,35E-01 32/37 (86%) HLA-DRB1,HLA-A,HLA-C,HLA-DPB1,HLA-DRB5
Production of 
Nitric Oxide 
and Reactive 
Oxygen Species in 
Macrophages
4,57088E-05 5,18E-02 183/193 (95%) NCF1,APOB,MPO,TYK2,CREBBP,PIK3C2G,NCF4,JAK2,PRKD3,ATM
CNTF Signaling 5,7544E-05 9,52E-02 57/63 (90%) LIFR,NRAS,TYK2,PIK3C2G,JAK2,ATM
Virus Entry 
via Endocytic 
Pathways
0,000114815 6,86E-02 95/102 (93%) NRAS,HLA-A,HLA-C,CLTCL1,PIK3C2G,PRKD3,ATM
Mouse Embryonic 
Stem Cell 
Pluripotency
0,000144544 6,60E-02 99/106 (93%) LIFR,NRAS,TYK2,CREBBP,PIK3C2G,JAK2,ATM
Table 1. Export of Ingenuity Pathway Analysis of 229 genes with at least one damaging mutation showing the 
top 16 most significant Canonical Pathways across the entire dataset. The significant values for the canonical 
pathways are calculated by Fisher’s exact test right-tailed. The ratio is calculated by the number of genes from 
the analysis list (229) in the given pathway, divided by the total number of genes that make up that pathway. All 
molecules involved are shown in the last column.
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vivo state more accurately, and enable the preservation of the original tissue’s functionality. We tested the 3D 
growth ability of MUG-Mel2 to see if cells are able to form spheroids and if the intense stable pigmentation of cells 
can be reflected. The wood based NFC hydrogel presents an optimal matrix for the cells, to maintain their natural 
behavior and to increase the deep brown staining (see Fig. 5A–C and F).
Incidence of melanoma has been increasing in recent years, therapies for BRAF mutated mela-
noma currently exist however, a considerable part of melanoma can still not be treated despite inten-
sive research. Therefore the detection of new treatment targets and therapies is urgently needed. The 
Ras/Raf/MEK/ERK pathway, involved in the control of growth signals, cell survival and invasion 
play a major role in melanomas. Melanomas are known to harbour activating mutations in RAS and/
or BRAF suggesting that the downstream effector Extracellular signal-regulated kinase (ERK) may be 
playing a major role in the oncogenic behavior of these tumors10. Activation of ERK1/2 was observed 
by immunohistochemistry in 54% of primary and 33% of metastastic melanomas, respectively11, 
MUG-Mel2 presents a high activated (phosphorylated) ERK1/2, significant more activated compared to WM 
164, a BRAF mutated cell line. In 1970 Lee and Merrill discovered that melanomas are heterogeneous and that 
different clinical appearance is also associated with different distributions by site and age with different out-
comes12. Melanomas with NRAS mutation account for approximately 25% of all melanomas, most commonly 
mutations are observed in codons 12, 13 and 61 which leads to aberrant cell proliferation13, metastasis14, 
and chemo-resistance15, 16. Many other cancer types also show NRAS mutation with an important clinical impact 
on the overall population in view of tumor incidence, mortality and survival17. NRAS is a frequently UV-mutated 
oncogene, generally occurring in melanoma of the skin in UV exposed areas, which is proven by characteristic 
base changes in the DNA (C > T transition). This common change is also seen in MUG-Mel2, which demon-
strates a high portion of C > T transitions (>50%). We were able to analyze a variety of mutations with the tar-
geted exome sequencing analysis. For a better overview the mutations were summarized in damaging mutations 
and the amount of mutations was evaluated with the ingenuity canonical pathway analysis. MUG-Mel2 presents 
among other mutated genes involved in DNA damage. DDR (DNA damage response) signaling pathway is the 
central regulation network in response to DNA damage, key proteins are ATM and ATR kinases, both are acti-
vated upon DNA damage and DNA replication stress18. ATM (ataxia telangiectasia mutated) or ATR (ataxia 
telangiectasia and Rad3-related protein) one of the DNA-damage checkpoint pathways, depending on generating 
double-stranded-break (DSB) or single-stranded-break DNA (ssDNA)19, revealed an important issue for can-
cer development. Interestingly ATM, located on chromosome 11, showed a balance CNV profile of ATM gene, 
whereas one non synonymous mutation (ATM p.T373K) was found. ATR located on chromosome 3, best known 
for its role in the activation of checkpoint kinase 1 (ChK1)20, presented a gain in MUG-Mel2, and additionally 
one non synonymous mutation (ATR p.K764E). ATR is essential for cell survival, knocking out of ATR in mice 
leads to embryonic death whereas in contrast ATM is not essential for cell survival20. So far no inhibitors of ATR 
have yet been developed. However, Chk1 and Chk2 are critical kinases downstream of both. ATM and ATR play 
roles in cell cycle arrest, DNA repair or apoptosis, and are valuable for further investigation. Wei et al. performed 
exome sequencing on 14 metastatic melanomas and found among others GRIN2A mutation21. The presence of 
Figure 7. Canonical Pathway of ‘CREB Signaling in Neurons’ (IPA, p-value 3.02E-05). Color red: the darker, 
the more damaging mutations were found by exon sequencing. Color pink: overlap of genes within dataset of 
282 damaging mutations. Color pink double bordered: shows more than one gene within a complex. Genes 
from the dataset involved in the pathway are: PRKDC, NRAS, TYK2, CREBBP, PIK3C2G, ATR, JAK2, PRKD3, 
ATM.
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glutamate receptor GRIN2A, which encodes N-methyl-(D)-aspartic acid (NMD) was also confirmed in other 
high-throughput sequencing studies22. Mutation of glutamate receptor (mGluRs), GRMR3 (glutamate metapo-
tropic receptor 3) and PLCB4, an enzyme that catalyzes the formation of IP3 (inositol triphosphate) and DAG 
(diacylglycerol) downstream of mGluRs, seems to play an important role in melanoma21. While there is a long list 
of genes mutated in melanoma, we want to underline and emphasize mutations belonging to glutamate receptors 
and related pathways. GRIN2A, found on chromosome 16p13.2, bears the agonist binding side for glutamate. 
We observed two mutations (p.E962K and p.G1243G) in MUG-Mel2. Wei et al. discovered GRIN2A mutations 
in 6 of 14 melanoma samples, and PLCB4 (4 from 14 melanoma samples bearing a mutation). However, so far 
the tumorigenic effect of GRIN2A and PLCB4 is unclear. MUG-Mel2 presents one non synonymous mutation in 
PLCB4 and one non synonymous mutation in GRM3. GRM3, a metabolic glutamate receptor also activated by 
glutamate is mutated in 16% (13 of 80 tumors) of melanoma cases23. Prickett et al. showed that GRM3 promotes 
the proliferation and migration behavior of melanoma cells and mutated GRM3 clones are more susceptible 
to MEK inhibitors, AZD-624423. Furthermore two GRM3 mutated cell lines exhibited anchorage-independent 
growth and increased migration mediated by MAPK signaling24. Further studies will need to address whether 
mutations of GRM3 or GRIN2A are the reason for tumorigenicity or aggressiveness in melanoma cells.
To conclude, the newly established cell line MUG-Mel2 presented, due to its phenotypically and genotypically 
precise characterization, aggressive and fast growing behavior in mouse and chick models. In particular, with the 
high pigmentation the cell line is a promising new model for innovative NRAS therapy options.
Methods
Patient History. The cell line was obtained from a fresh specimen of a cutaneous metastasis of a 48-year-old 
male patient with a cutaneous primary, ulcerated melanoma (8.5 mm thickness) on the left shoulder. Sentinel 
node biopsy of the left axilla revealed a positive node and subsequent elective lymph node dissection revealed 
additional two positive out of 18 excised nodes. Only four months after wide surgical excision of the primary 
melanoma, the patient developed multiple cutaneous satellite metastases around the scar with progressive spread 
Figure 8. Canonical Pathway of ‘Molecular Mechanisms of Cancer’ (IPA, p-value 0.0199). Color red: the 
darker, the more damaging mutations were found by exon sequencing. Color pink: overlays within dataset of 
282 damaging mutations. Color pink double bordered: shows more than one gene within a complex. Genes 
from the dataset involved in the pathway are: PRKDC, NRAS, TYK2, CREBBP, PIK3C2G, ATR, JAK2, PRKD3, 
ATM.
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all over the body (Fig. 2A). In addition multiple lung metastases were detected. Genetic analysis of the primary 
tumor and one cutaneous metastasis presented a mutation in NRAS p. Q61R. No mutations in BRAF or c-kit were 
detected. Based on the genetic analysis, treatment with a MEK inhibitor was initiated. After three months of the 
treatment, there was no objective evidence of response as the patient continued to develop multiple cutaneous 
metastases. Radiological staging moreover showed a rapid progression with new brain, liver and lung metasta-
ses. The treatment with MEK inhibitor was discontinued and he received two cycles of dacarbazine without any 
clinical benefit. At month one, after the diagnosis of the primary melanoma and a rapid progress, a last attempt to 
treat with CTL4-antibody ipilimumab was made. However, the patient died from brain metastases shortly after 
first administration of ipilimumab.
Cell Culture. The tumor tissue (cutaneous metastasis) was obtained immediately after surgery, followed by 
mechanical disaggregation of the tumor tissue into approximately 1–2 mm3 pieces. Cells were cultured in RPMI 
(Life Technologies, Carlsbad, CA) containing 10% fetal bovine serum (FBS, Biochrom AG, Berlin, Germany), 
2 mM L-glutamine (Life Technologies), and 1% penicillin/streptomycin (Pen/Strep, Life Technologies). The mel-
anoma cells, named MUG-Mel2, grew at a pH of 7.4. Cells were grown to 80% confluence and detached from 
the flasks with Accutase (Sigma Aldrich, Vienna, Austria). Incubation of all cells was carried out at 37 °C in a 
humidified atmosphere of 5% CO2. All cells were periodically checked for mycoplasma by PCR. The study was 
approved by the local ethics committee board of the Medical University of Graz (vote #18–192ex06/07; valid until 
17.04.2016) and the patient gave written informed consent for the study specific procedure. We confirm that all 
experiments were performed in accordance with relevant guidelines and regulations.
MTS Assay and xCELLigence. 10,000 MUG-Mel2 cells per well and 10,000 cells isolated from the 
xenotransplanted NSG mice were seeded into 96 well microtiter plates and the Cell Titer 96 Aqueous 
Non-Radioactive Cell Proliferation Assay Kit (Promega, Madison, WI) was performed according to manufactur-
er’s recommendations. The incubation time was 24, 48 and 72 hours, respectively. Culture medium was used as 
background value. The viability was determined colorimetrically by absorbance at 490 nm.
Cell proliferation was measured using the xCELLigence Real-Time Cellular Analysis system (OLS OMNI Life 
Science Bremen, Germany). Briefly, the background impedance was measured following the addition of 100 μL 
of medium to the 16-well E-plates (OLS). Cell suspensions containing various amount of cells (7.5 × 103, 1 × 104, 
2 × 104, 2. × 104 cells) in 100 μL medium were seeded into the wells according to the instructions in the user’s 
manual. The different amounts of cells were performed in quadruplicates. Proliferation was monitored every 
twenty minutes. Impedance changes expressed as cell index (CI) were automatically calculated and correlated 
with cell growth over a period of 100 h using the RTCA software (OLS). Doubling time was calculated from 
2. × 104 cells.
Immunohistochemistry. Immunostaining was performed using the Envision Plus detection system (Dako, 
Carpinteria, CA) and the Ultra-Vision LP detection system (Thermo Scientific, Fremont, USA) according to the 
manufacturer’s instructions. All specimens from the patient as well as the cell culture were stained with antibodies 
against Melan-A, S-100 protein, Tyrosinase, HMB-45. For CAM assay xenografts, anti-Ki-67 was used for the 
analysis of mitotic active cells (clone MIB-1), Anti-Desmin to detect newly formed vessels. All antibodies were 
obtained from DAKO. Spheroid staining: cell nucleoli were stained with Hoechst and proliferation with Ki-67 
(eBioscience, San Diego, CA). Appropriate positive and negative controls were included.
Cell Cycle. Cells were harvested by trypsinization and fixed with 70% ice-cold ethanol for 10 min at 4 °C. 
After washing with PBS, the cell pellet was re-suspended in PI-staining buffer (50 µl/ml PI, RNAse A, Beckman 
Coulter, Brea, CA) and incubated for 15 min at 37 °C. Cells were spiked with mononuclear cells (MNC), positive 
diploid population control and then analyzed by FACS LSRII (BD Biosciences). A minimum of 10,000 events per 
sample was acquired and data were determined by using FACS DIVA software (BD Biosciences). DNA index was 
calculated by geometric mean M2 (MUG-Mel2)/geometric mean M1 (MNC).
Cell Forming Units (CFUs). Two six well plates (Corning Inc., Corning, NY) were seeded with 400 cells per 
well and incubated at 37 °C and 5% CO2 for 30 days for colony formation. After the incubation time, melanoma 
cells were washed with PBS, fixed with 4% formaldehyde and stained with 1 mg/ml Crystal Violet, after washing 
with PBS, colonies were counted and mean value was formed.
3D cell Culturing with Nanofibrillar Cellulose Hydrogel. Sterile GrowDex™ nanofibrillar cellulose 
(NFC) hydrogel was obtained from UPM-Kymmene Corporation, Finland. The NFC concentration of the hydro-
gel was 1.55 wt%. To determine the optimal conditions for 3D cell culturing, three concentrations (0.4%; 0.7% 
and 1% wt/v) of NFC hydrogel, as well as two cell-seeding concentrations (50,000 and 100,000 cells per 100 ul 
of NFC / 96-well) were tested. MUG-Mel2 spheroids grown in 0.4% NFC hydrogel were collected at day three 
for live calcein staining. Prior to collection, NFC hydrogel was digested from the cell culture by cellulase enzyme 
(VTT, Finland) for 24 h at 37 °C using 300 µg of cellulose per 1 mg of NFC. Spheroids were washed three times 
with 1xDPBS, suspended in staining solution containing Calcein-AM 1:500 (Cellstain double staining kit; Sigma 
Aldrich) and 50 µg/ml DAPI (Invitrogen, Carlsbad, CA) for 15 min at 37 °C, and subsequently mounted using 
Prolong Diamond Antifade Mountant (Life Technologies). Fluorescent images were taken with the Leica TCS SP5 
microscope using HCX PL APO 20x/0.7 objective. Imaris 8.4.1 software was used for image acquisition.
Ex ovo CAM Assay. Fertilized Lohmann white classic chicken eggs from local hatchery were incubated at 
37.6 °C and 70% humidity. The egg shell was cracked on day three of chick development and the embryo decanted 
to a sterile dish. On day 10, 10E6 MUG-Mel2 cells/xenograft (n = 12) were re-suspended in 15 μl PBS and 5 μl 
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Matrigel matrix (BD, Biosciences) and grafted in the center of a 5 mm silicon ring on the surface of the chorion-
allantoic membrane (CAM). Xenografts were photographed using a stereo-microscope (Olympus SZX16) and 
excised with the surrounding CAM five days after seeding, fixed in 4% paraformaldehyde and paraffin embedded. 
For subsequent analyses haematoxilin/eosin and immunostaining of 5 μm sections were performed to determine 
the tumor cell morphology.
Tumorigenicity. 2 × 106 MUG-Mel2 from passage 23 were re-suspended in 200 µl serum free medium and 
Matrigel (Corning) (1:1) and were subcutaneously injected into the right flank of three six-week-old female NOD/
SCID/IL-2rγnull (NSG-) mice (Charles River Laboratories, Sulzfeld, Germany). Five NU-Foxn1-nu (Charles 
River Laboratories), eight-weeks-old, female mice were xenotransplanted with 2 × 106 MUG-Mel2/100 µl 
serum free medium without Matrigel at passage 60. The cell suspension was inoculated subcutaneously into the 
right flank of the mice. The mice were observed daily. All animal work was done in accordance with a protocol 
approved by the institutional animal care and use committee at the Austrian Federal Ministry for Science and 
Research (BMWF) (vote 66.010/0160-II/3b/2012).
Cell Line Identification Power Plex® 16 system. Frozen tumor tissue was dissected into small pieces 
and re-suspended in 180 μl ATL buffer from Qiagen (Vienna, Austria). The cell pellet (1 × 106) from MUG-Mel2 
(passage 9) was re-suspended in 200 μl PBS, 20 μl proteinase K. Afterwards, 200 μl AL buffer from Qiagen was 
added. DNA preparations were carried out using the QIAamp DNA Mini kit (Qiagen) according to the man-
ufacturer’s instructions. After normalizing the DNA, 0.7 ng DNA was amplified using Power Plex 16 System 
(Promega) in a 10 μl reaction. The product (1 μl) was mixed with Hi-Di formamide (Applied Biosystems Inc., 
Foster City, CA) and Internal Lane Standard (ILS600), denatured and fractionated on an ABI 3730 genetic ana-
lyzer. Resulting data were processed and evaluated using ABI Genemapper 4.0.
Copy Number Profiling. Genome wide copy number aberrations (CNA) were established using 
low-coverage whole genome sequencing. Shotgun libraries were prepared using the TruSeq DNA LT Sample 
preparation Kit (Illumina, San Diego, CA) with slight modifications to the manufacturer’s protocol. Briefly, 
380 ng, 144 ng and 360 ng input DNA from MUG-Mel2 were fragmented in 130 µl using the Covaris System 
(Covaris, Woburn, MA, USA). After concentrating the volume to 50 µl end repair, A-tailing and adapter ligation 
were performed following the manufacturer’s instructions. For selective amplification of the library fragments 
that have adapter molecules on both ends we used 15 PCR cycles for the higher concentrated samples, i.e. primary 
melanoma tumor from the skin, MBM tissue resulting MUG-Mel2 cell line. Libraries were quality checked on an 
Agilent Bioanalyzer using a DNA 7500 Chip (Agilent Technologies, Santa Clara, CA) and quantified using qPCR 
with a commercially available PhiX library (Illumina, San Diego, CA) as a standard. Libraries were pooled equi-
molarily and sequenced on an Illumina MiSeq in a 150 bp single read run. On completion of the run data were 
base called demultiplexed on the instrument (provided as Illumina).
Targeted Exome Sequencing. Targeted exome sequencing of MUG-Mel2 cell line was performed using 
the TruSight One sequencing panel (Illumina), which targets 11,946,514-bp exon regions in 4,813 genes. Libraries 
were obtained following manufacturer´s instructions and sequenced using the MiSeq next-generation sequencer 
(Illumina). At least 96% of the target had a depth of coverage >20X, with a mean depth of coverage of 105X. The 
extracted variants were annotated using the Variant Studio software (Illumina). Variants with a reported fre-
quency < 1% according to the 1000 Genome project annotation were considered as somatic variants.
Pathway analysis were performed with Ingenuity Pathway Analysis, IPA-version 2781452; Build: ‘ing_jakku’ 
(QIAGEN, Ingenuity Systems; www.ingenuity.com). A core analysis was performed to get an insight on which 
pathways or functional groups these genes are related to. IPA setting was filtered on human molecules and/or 
relationships as well as melanoma cell lines such as M14 or LOX IMVI or UACC-257 or Melanoma Cell Lines 
not otherwise specified or other Melanoma Cell Lines or SK-MEL-2 or SK-MEL-5 or UACC-62 or A375 or 
SK-MEL-28 or MALME-3M.
Western blot analysis. For immunoblotting, whole cell protein extracts from MUG-Mel2 and WM164 
were prepared with lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM NaF, 1 mM EDTA, 1% NP-40, 
1 mM Na3 VO4, and protease inhibitor cocktail (P8340; Sigma Aldrich), subjected to SDS-PAGE and blotted 
onto Amersham™ Protran™ Premium 0.45 µM nitrocellulose membrane (GE healthcare Life science, Little 
Chalfont, UK). All steps were performed on ice. Protein concentration was determined with the Pierce BCA 
Protein Assay Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. Primary antibodies against 
p44/42 MAPK (ERK 1/2), phospho-p44/42 MAPK (ERK 1/2), and β-actin were purchased from Cell Signaling 
Technology (Cambridge, UK). Blots were developed using a horseradish peroxidase- conjugated secondary anti-
body (Dako, Jena, Germany) at room temperature for 1 h and the Amersham™ ECL™ prime western blotting 
detection reagent (GE Healthcare), in accordance with the manufacturer’s protocol. Chemiluminescence signals 
were detected with the ChemiDocTouch Imaging System (BioRad Laboratories Inc., Herkules, CA) and images 
were processed with the ImageLab 5.2 Software (BioRad Laboratories Inc.).
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